top of page
Search


Vicadrostat ± Empagliflozin: Consistent Albuminuria Reduction Across CKD Risk Subgroups
Written by Agavriloaei Bogdan Dumitru Reviewed by @ Sophia Ambruso, Priya John. The question: Does the aldosterone synthase inhibitor vicadrostat consistently reduce albuminuria across the CKD risk strata represented in the study, including patients with uncontrolled hypertension or those receiving diuretics? To respond, we have the next article: https://www.sciencedirect.com/science/article/pii/S2468024926027774 Background: The Renin-Angiotensin-Aldosterone System (RAAS) T
Bogdan MD
24 minutes ago7 min read


Real-Time, Multidisciplinary Approach of Women With Pregnancy-Associated Thrombotic Microangiopathy Where did all the aHUS go?
Written by Cristina Popa MD Reviewed by Sophia Ambruso MD A woman is three days postpartum. Her platelet count is falling, creatinine is rising, and the peripheral blood smear shows schistocytes. The laboratory phenotype is unmistakably thrombotic microangiopathy (TMA); the underlying diagnosis is not. HELLP syndrome, thrombotic thrombocytopenic purpura (TTP), and complement-mediated atypical hemolytic uremic syndrome (aHUS) can initially produce remarkably similar clinical
Cristina Popa, MD
Oct 1412 min read


Recurrent IgAN After Transplant: A New Target, but Is the Evidence Enough?
Telitacicept in Posttransplant IgA Nephropathy, does this change how we think about the disease in the transplant patient?
Akshaya Jayachandran, DM
Jul 47 min read
bottom of page

.png)